It has been reported that activation might be a prognostic marker for radiotherapy in HNSCC and indicates PI3K pathway inhibition would potentially exert a synergistic effect with radiotherapy 62. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.